Asthma — Prediction of 30-Day Readmission Using Machine Learning
Citation(s)
Arvind V, London DA, Cirino C, Keswani A, Cagle PJ Comparison of machine learning techniques to predict unplanned readmission following total shoulder arthroplasty. J Shoulder Elbow Surg. 2021 Feb;30(2):e50-e59. doi: 10.1016/j.jse.2020.05.013. Epub 2020 Jun 9.
Bolourani S, Tayebi MA, Diao L, Wang P, Patel V, Manetta F, Lee PC Using machine learning to predict early readmission following esophagectomy. J Thorac Cardiovasc Surg. 2021 Jun;161(6):1926-1939.e8. doi: 10.1016/j.jtcvs.2020.04.172. Epub 2020 May 29. Erratum in: J Thorac Cardiovasc Surg. 2020 Oct 17;:.
Li Q, Yao X, Échevin D How Good Is Machine Learning in Predicting All-Cause 30-Day Hospital Readmission? Evidence From Administrative Data. Value Health. 2020 Oct;23(10):1307-1315. doi: 10.1016/j.jval.2020.06.009. Epub 2020 Sep 7.
Loreto M, Lisboa T, Moreira VP Early prediction of ICU readmissions using classification algorithms. Comput Biol Med. 2020 Mar;118:103636. doi: 10.1016/j.compbiomed.2020.103636. Epub 2020 Feb 1.
Merrill RK, Ferrandino RM, Hoffman R, Shaffer GW, Ndu A Machine Learning Accurately Predicts Short-Term Outcomes Following Open Reduction and Internal Fixation of Ankle Fractures. J Foot Ankle Surg. 2019 May;58(3):410-416. doi: 10.1053/j.jfas.2018.09.004. Epub 2019 Feb 23.
Morel D, Yu KC, Liu-Ferrara A, Caceres-Suriel AJ, Kurtz SG, Tabak YP Predicting hospital readmission in patients with mental or substance use disorders: A machine learning approach. Int J Med Inform. 2020 Jul;139:104136. doi: 10.1016/j.ijmedinf.2020.104136. Epub 2020 Apr 18.
Xue Y, Klabjan D, Luo Y Predicting ICU readmission using grouped physiological and medication trends. Artif Intell Med. 2019 Apr;95:27-37. doi: 10.1016/j.artmed.2018.08.004. Epub 2018 Sep 10.
Prediction of 30-Day Readmission Using Machine Learning
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
